Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor
Summary
This summary is machine-generated.Leukemia inhibitory factor (LIF) transiently activates JAK-STAT signaling. SHP-1 phosphatase and SOCS-3 protein provide negative feedback, regulating LIF
Area Of Science
- Endocrinology
- Molecular Biology
- Cell Signaling
Background
- Leukemia inhibitory factor (LIF) is a cytokine that stimulates the hypothalamo-pituitary-adrenal (HPA) axis.
- LIF signaling involves Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway activation.
Purpose Of The Study
- To investigate the negative regulatory mechanisms of LIF-induced signaling in corticotrophs.
- To elucidate the roles of SHP-1 phosphatase and SOCS-3 in controlling LIF-mediated JAK-STAT activation.
Main Methods
- Western blotting to assess protein phosphorylation (JAK2, STAT3).
- Luciferase reporter assays to measure proopiomelanocortin (POMC) promoter activity.
- Co-immunoprecipitation and overexpression studies of SHP-1 and SOCS-3.
Main Results
- LIF-induced JAK2 and STAT3 phosphorylation were transient, with dephosphorylation mediated by SHP-1.
- SHP-1 negatively regulates LIF-induced POMC promoter activity.
- SOCS-3 directly binds to JAK2, leading to its inactivation and degradation, thus inhibiting LIF signaling.
Conclusions
- LIF-induced corticotrophic signaling is subject to dual negative autoregulation.
- SHP-1 dephosphorylates JAK2 and STAT3, while SOCS-3 mediates JAK2 inactivation.
- These mechanisms ensure proper control of the HPA axis response to LIF.
View abstract on PubMed